ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
54 announcements
Record Q2 revenue of ₹538 Cr (+35%) and EBITDA of ₹151 Cr (28% margin), but gross margin fell roughly 700 bps and management deflected several key questions.
Shilpa Medicare reports NCLAT set aside the CIRP against its subsidiary FTF Pharma, annulling the process. The filing states no impact on the listed entity.
Q2 FY27 revenue INR 538 cr (+45% YoY), EBITDA INR 151 cr (28% margin), PAT INR 79 cr (+80%). 1HFY27 total income INR 1,007 cr (+44%). Strategy: complex FDF launches, CDMO, biologics, rHA.
Shilpa Medicare Ltd reported revenue from operations of ₹529.1 Cr (+43.0% YoY) and net profit of ₹79.2 Cr (+79.6% YoY) for Q2 FY27.
Shilpa Medicare's board meeting is scheduled for 5 November 2026 to approve Q2 and H1 unaudited financial results. The trading window remains closed until 7 November 2026.
Shilpa Medicare Limited’s Unit 4 in Jadcherla received GMP certification from AGES, Austria, following a successful inspection. This milestone enables operations for European and global markets.
Shilpa Medicare Ltd has filed its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Shilpa Medicare Ltd KMP Alpesh Maheshkumar Dalal sold 4,000 equity shares via market sale. The transaction was valued at Rs.0.42 Crore and executed on the NSE.
The company's promoters reported the release of encumbrance on 30,00,000 equity shares held by them. This reduction in pledged shares signals a change in promoter leverage.
Shilpa Medicare received a 'Crisil ESG 59' rating from CRISIL ESG Ratings for FY2026. This is a routine regulatory disclosure under Regulation 30 with no financial implications.
Shilpa Medicare reported a USFDA surveillance inspection at its Unit VII Analytical Services Division. The inspection resulted in one procedural observation with no material impact on operations.
Shilpa Medicare secured final CDSCO-SEC approval for OERIS™, a world-first extended-release ondansetron injection patented until 2039. Commercial launch in India is planned upon final marketing authorization.
Shilpa Medicare's 39th AGM held 11 September 2026 via VC. Resolutions covered financial statement adoption, ₹0.60/share dividend, and director re-appointment.
NCLT Ahmedabad admitted FTF Pharma, Shilpa Medicare's subsidiary, to CIRP over a ₹2.18 Crore debt. IRP appointed with moratorium; impact on parent unquantifiable.
Shilpa Medicare has dispatched letters to shareholders with unregistered emails, providing web-links to access the Annual Report and Notice of the 39th Annual General Meeting.
Shilpa Medicare clarified a news report regarding a voluntary recall of 27,923 vials of Pemetrexed Injection in the US. The company expects no material impact on operations.
Shilpa Medicare Limited filed its Annual Report for the financial year 2025-26. The document also contains the notice convening the 39th Annual General Meeting.
Shilpa Medicare Limited has issued the notice for its 39th Annual General Meeting scheduled for September 11, 2026. The meeting will be held via video conferencing.
Shilpa Medicare reported record Q1FY27 revenue of INR 469cr, up 43% YoY, with EBITDA margins hitting 30%. Strategy focuses on high-margin CDMO, Biologics, and complex formulations.
Shilpa Medicare Limited announced its Annual General Meeting on September 11, 2026. The agenda includes adopting financial statements and declaring a ₹0.60 per share dividend.
Shilpa Medicare Limited has fixed September 4, 2026, as the record date for final dividend entitlement. Payment is subject to shareholder approval at the upcoming September AGM.
Shilpa Medicare Ltd reported revenue from operations of ₹465.8 Cr (+44.9% YoY) and net profit of ₹100.9 Cr (+115.1% YoY) for Q1 FY27.
Shilpa Medicare appointed Dr. Uday N. Harle as CEO of its wholly owned subsidiary, Shilpa Biologicals Private Limited. The appointment is effective from August 3, 2026.
Shilpa Medicare delivered a robust Q4 performance with revenue growing 30% YoY, driven by API and formulation scale-ups, but remains heavily dependent on lumpy licensing income and future global clinical trial successes.
Shilpa Medicare scheduled a board meeting for August 5, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
India Ratings assigned IND A+/Stable/IND A1+ ratings to Shilpa Biologicals' Rs 125 Crore bank facilities. This subsidiary rating reflects the group's credit profile.
Dr. Sridevi Khambhampaty resigned as CEO of Shilpa Biologicals Private Limited, effective 15 July 2026. The resignation from the material subsidiary is due to personal commitments.
Shilpa Medicare's bank loan facilities were upgraded to IND AA- by India Ratings. The rating reflects improved creditworthiness, with a Stable Outlook.
Shilpa Medicare's board approved FY26 financials and a ₹0.60/share dividend. It also greenlit a ₹4.44 Crore investment in Neo Green Power for 28% equity.
Shilpa Biologicals has entered a co‑development and supply agreement with Finland's Orion for a nivolumab biosimilar. The partnership expands Shilpa's European market footprint.